false 0001645469 0001645469 2025-02-19 2025-02-19
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 19, 2025
 
MONOPAR THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-39070
  
32-0463781
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification No.)
 
1000 Skokie Blvd., Suite 350, Wilmette, IL
  
60091
(Address of principal executive offices)
  
(Zip Code)
 
(847) 388-0349
Registrant’s telephone number, including area code
 
N/A
(Former name or former address, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.001 par value
 
MNPR
  
The Nasdaq Stock Market LLC (Nasdaq Capital Market)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
 
Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.
 
On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board. The Corporate Governance and Nominating Committee of the Board found her to be qualified under the standards established by the Committee and to meet the standards of independence applicable to directors of companies listed on the Nasdaq Capital Market and recommended her to be appointed to the Board.  Ms. Talukdar, upon recommendation of the Corporate Governance and Nominating Committee, was also appointed to the Audit Committee, the Compensation Committee, the Corporate Governance and Nominating Committee and the Plan Administration Committee. Ms. Talukdar will serve on the Board until the Company’s next annual meeting of stockholders or until her successor is duly elected and qualified.
 
Ms. Talukdar currently serves as Senior Vice President, Head of Investor Relations at Moderna Inc. and has held this role since April 2019. She brings over 20 years of experience in investor relations, healthcare investments, and financial strategy. Before joining Moderna, Ms. Talukdar was a Senior Portfolio Manager at Abu Dhabi Investment Authority (“ADIA”), overseeing global healthcare investments, and previously served as a Partner and Healthcare Equity Analyst at Lord Abbett & Co. She also held investment roles at MFS Investment Management and State Street Global Advisors. Ms. Talukdar received her B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.
 
There is no arrangement or understanding between Ms. Talukdar and any other person pursuant to which she was appointed as a director. There are no transactions between Ms. Talukdar or any member of her immediate family and the Company or any of its subsidiaries that would be reportable as a related party transaction under the rules of the United States Securities and Exchange Commission.
 
Ms. Talukdar will be entitled to receive the standard compensation for non-employee directors.
 
Item 9.01 Financial Statements and Exhibits
 
Exhibit No.  
  
Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Monopar Therapeutics Inc.
  
       
Date: February 24, 2025
By:
/s/ Karthik Radhakrishnan
  
 
Name:
Karthik Radhakrishnan
  
 
Title:
Chief Financial Officer
  
 
 
v3.25.0.1
Document And Entity Information
Feb. 19, 2025
Document Information [Line Items]  
Entity, Registrant Name MONOPAR THERAPEUTICS INC.
Document, Type 8-K
Document, Period End Date Feb. 19, 2025
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39070
Entity, Tax Identification Number 32-0463781
Entity, Address, Address Line One 1000 Skokie Blvd.
Entity, Address, Address Line Two Suite 350
Entity, Address, City or Town Wilmette
Entity, Address, State or Province IL
Entity, Address, Postal Zip Code 60091
City Area Code 847
Local Phone Number 388-0349
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol MNPR
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001645469
Monopar Therapeutics (NASDAQ:MNPR)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Monopar Therapeutics 차트를 더 보려면 여기를 클릭.
Monopar Therapeutics (NASDAQ:MNPR)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Monopar Therapeutics 차트를 더 보려면 여기를 클릭.